Results 121 to 130 of about 638,982 (265)
Knowledge, Attitudes, and Practices Regarding Oral Cancer Among Patients with Oral Cancer in Hunan Province, China: A Cross-Sectional Study. [PDF]
Lu Y +6 more
europepmc +1 more source
Temozolomide treatment activates GSK3β, driving DNMT1 phosphorylation, destabilization, and CD47 promoter hypomethylation in glioblastoma. This epigenetic shift upregulates CD47, enabling TMZ‐treated GBM cells to evade macrophage phagocytosis, survive chemotherapy, and acquire resistance.
Jie Li +11 more
wiley +1 more source
Feasibility Study of an Assay Measuring Activity of Oral Cancer Protease Mixtures to Cleave Protease-Activated Receptor 2, an Oral Cancer Pain Mediator. [PDF]
Ramirez-Garcia PD +4 more
europepmc +1 more source
Lai et al. find that m6A reader YTHDC1 is specifically overexpressed in triple‐negative breast cancer (TNBC) and orchestrates glucose and glutamine metabolism in an m6A‐dependent manner to confer robust adaptability to lethal metabolic stress. Leveraging YTHDC1 knockdown‐induced metabolic vulnerability, an ATF4 mRNA‐targeted nanotherapy is developed to
Zheng‐Hao Lai +12 more
wiley +1 more source
Analysis of Dietary Patterns Containing Curcumin and Oral Cancer. [PDF]
Zhao YY +5 more
europepmc +1 more source
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang +21 more
wiley +1 more source
How oral cancer is taught: a scoping review. [PDF]
Tiwari L, Kujan O.
europepmc +1 more source
The DLST K409 succinylation mediated by CPT1A promotes OXPHOS and redox homeostasis through regulating enzyme activity, thereby promoting the malignant progression of LUAD. Notably, the succinylation of DLST can enhance the cuproptosis resistance by inhibiting its lipoylation.
Xuanxuan Li +9 more
wiley +1 more source
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu +7 more
wiley +1 more source

